Key result
Prolonged oral treatment with cholecalciferol decreased blood pressure and restored the relaxant and hyperpolarizing responses to bradykinin in spontaneously hypertensive rats.
Why the study?
Does cholecalciferol treatment improve bradykinin-induced vasodilation in spontaneously hypertensive rats?
Does cholecalciferol treatment improve bradykinin-induced vasodilation in spontaneously hypertensive rats?
Cholecalciferol restores bradykinin-induced relaxation in hypertensive rat arteries by improving Ca2+-dependent K+ channel function, contributing to blood pressure reduction.
Cholecalciferol effects in hypertensive rats should not change practice; leaves open translation to human hypertension trials.
The vasodilation and hyperpolarization induced by bradykinin (BK) in the mesenteric vascular bed and mesenteric arteries from spontaneously hypertensive rats (SHR) and from normotensive Wistar rats (NWR), as well as Wistar Kyoto rats (WKY), was investigated before and after prolonged oral treatment with cholecalciferol (125 mg kg(-1) body weight per day) for 3 weeks. The cholecalciferol treatment caused a decrease in the SHR blood pressure, as well as a normalization in the resting potential of the smooth muscle cell membrane of mesenteric arteries and restored their hyperpolarizing response to BK. The concentration-response curves for the vasodilator effect of BK on the mesenteric vascular bed were significantly decreased in SHR and in WKY when compared with NWR. Cholecalciferol treatment improved the maximum responses of the SHR preparation, bringing them to levels similar to those of the NWR preparations, which themselves were unaffected by the treatment. In the presence of apamin, a Ca(2+)-dependent K(+) channel inhibitor, the maximum responses to BK in preparations from NWR or cholecalciferol-treated SHR decreased to values similar to those observed in untreated SHR. Our results indicate that the low responsivity of the SHR resistance vessels to the relaxant effect of BK is due to impaired Ca(2+)-dependent K(+) channels and that reversion of this impairment contributes to the blood pressure reduction caused by the cholecalciferol treatment. However, the mechanism of the low responsivity in WKY remains to be investigated.
No takes yet. Share an insight, caveat, or question.
Borges et al. (2002) studied Hypertension. Cholecalciferol vs. Untreated rats / Normotensive Wistar rats was evaluated on Vasodilation and hyperpolarization induced by bradykinin and blood pressure. Prolonged oral treatment with cholecalciferol decreased blood pressure and restored the relaxant and hyperpolarizing responses to bradykinin in spontaneously hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: